11/18
09:12 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/16
12:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/14
06:45 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/14
10:12 am
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Piper Sandler from $12.00 to $22.00. They now have a "neutral" rating on the stock.
Low
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Piper Sandler from $12.00 to $22.00. They now have a "neutral" rating on the stock.
11/13
05:00 pm
tvtx
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/12
06:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/12
04:05 pm
tvtx
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Low
Report
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
11/10
11:00 am
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/8
12:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/7
09:10 pm
tvtx
Travere Therapeutics Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
High
Report
Travere Therapeutics Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
11/7
09:05 pm
tvtx
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
High
Report
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
11/7
04:01 pm
tvtx
Travere Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Travere Therapeutics Announces Proposed Public Offering of Common Stock
11/6
04:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/4
04:30 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/4
04:30 pm
tvtx
Travere Therapeutics to Present at Upcoming Investor Conferences
Low
Report
Travere Therapeutics to Present at Upcoming Investor Conferences
11/2
12:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
11/1
11:27 am
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Scotiabank from $23.00 to $27.00. They now have a "sector outperform" rating on the stock.
Low
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Scotiabank from $23.00 to $27.00. They now have a "sector outperform" rating on the stock.
11/1
10:35 am
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "overweight" rating on the stock.
Low
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "overweight" rating on the stock.
10/31
04:30 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
10/31
07:00 am
tvtx
Travere Therapeutics Reports Third Quarter 2024 Financial Results
Low
Report
Travere Therapeutics Reports Third Quarter 2024 Financial Results
10/29
12:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
10/27
12:00 pm
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
10/26
07:04 am
tvtx
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 [Yahoo! Finance]
Low
Report
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024 [Yahoo! Finance]
10/26
07:01 am
tvtx
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
Low
Report
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
10/25
11:00 am
tvtx
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX